9 recruiting. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 9 |
| Phase 2 | 2 | Recruiting 2 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies BL-M24D1 - Multiple Myeloma, Hematologic Malignancies | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 33 | 2026-03-25 | 2026-06-04 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies INCA036873 - Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Incyte Corporation | 280 | 2026-01-08 | 2026-10-09 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. RJK-RT2831 dose-escalation phase Ia, RJK-RT2831 Dose Expansion Phase Ib - Hematologic Malignancies | Phase 1 | Recruiting | Nanjing RegeneCore Biotech Co., Ltd. | 71 | 2025-03-25 | 2026-01-30 |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer IM-1021 - Solid Malignancies, Hematologic Malignancies | Phase 1 | Recruiting | Immunome, Inc. | 190 | 2025-02-26 | 2026-08-10 |
| Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant Cyclophosphamide - Hematologic Malignancies | Phase 1 | Recruiting | Ronald Paquette | 26 | 2023-10-24 | 2026-08-05 |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... RIC, GVHD prophylaxis, allo HCT - HIV, Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 265 | 2023-01-26 | 2026-10-16 |
| Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment Pralatrexate Injection - Advanced Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Acrotech Biopharma Inc. | 24 | 2022-12-28 | 2026-02-11 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
Hematologic Neoplasms (9) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Renal Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Neoplasms (1) · Recurrence (1)
Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Neoplasms by Site (9) · Neoplasms (8) · Immune System Diseases (4) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Lymphatic Diseases (2) · Urogenital Diseases (2) · Adenocarcinoma (1) · Blood Protein Disorders (1) · Blood-Borne Infections (1) · Carcinoma (1) · Cardiovascular Diseases (1)
Cyclophosphamide (2) · 10-propargyl-10-deazaaminopterin (1) · Azacitidine (1) · Maraviroc (1) · Mycophenolic Acid (1) · Sirolimus (1) · Whole-Body Irradiation (1) · fludarabine (1) · plerixafor (1) · venetoclax (1)
National Cancer Institute (NCI) (2) · Acrotech Biopharma Inc. (1) · Immunome, Inc. (1) · Incyte Corporation (1) · Nanjing RegeneCore Biotech Co., Ltd. (1) · Ronald Paquette (1) · Sellas Life Sciences Group (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
United States (7) · China (3) · Denmark (2) · Australia (1) · Belgium (1) · France (1) · Italy (1) · Spain (1)
Christopher G Kanakry, M.D. (1) · Dragan Cicic, MD (1) · Erard Gilles, MD, MSc (1) · Mustafa A Hyder, M.D. (1) · Ronald Paquette, MD (1)
2025 (1)